www.mydario.com
OTCQB: DRIO This presentation of LabStyle Innovations Corp. (the “Company”) and statements of our management or agents related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our business, including many assumptions regarding future events. Words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate", "will", "would" and other similar expressions all denote forward-looking statements within the meaning of the Act. Readers are cautioned that actual results, performance, liquidity, financial condition and results of operations, prospects and opportunities could differ materially and perhaps substantially from those expressed in, or implied by, these forward-looking statements as a result of various risks, uncertainties and other factors. Factors that could cause or contribute to such differences include, but are not limited to our compliance with regulatory requirements, the impact of current and any future competition, our current and future capital requirements and our ability to satisfy our capital needs through financing transactions or otherwise, our ability to manufacture, market and generate sales of our Dario™ diabetes management solution, as well as other factors and risks discussed in the Company's filings (including the results of the company’s commercial and regulatory plans for Dario™) with the U.S. Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. In addition, readers are cautioned that any estimates, forecasts or projections contained in this presentation or as may be discussed by our management or agents have been prepared by our management in good faith on a basis believed to be reasonable. However, such estimates, forecasts and projections involve significant elements of subjective judgment and analysis and no representation can be made as to their attainability. No representation or warranty (express or implied) is made or is to be relied upon as a promise or representation as to our future performance. Readers are cautioned that such estimates, forecasts or projections have not been audited and have not been prepared in conformance with generally accepted accounting principles. Presentation Published: http://mydario.investorroom.com www.mydario.com
OTCQB: DRIO www.mydario.com
OTCQB: DRIO www.mydario.com
OTCQB: DRIO Reimbursement received USA Costa Rica Panama Canada Israel Italy Australia Soft Launch (UK/NZ) Netherland Q3/14 Q4/14 Q1/15 Q2/15 Q3/15 www.mydario.com
OTCQB: DRIO www.mydario.com
OTCQB: DRIO Estimated cost of diagnosed diabetes in 2012 was $245 billion, including $176 billion of direct medical costs and $69 billion in reduced productivity www.mydario.com
OTCQB: DRIO Glucose Monitoring, $12bn Therapy - Insulin, $54bn Diabetes caused at least $612 billion dollars in health expenditures globally in 2014 – 11% of total spending on adults (Source: International Diabetes Federation) www.mydario.com
OTCQB: DRIO Dario Mobile Management Platform iOS/Android Dario 24/7 Support Patients Engagement BG Measure Clinical Program Library Daily feedback to adjust and optimize treatment Dario provides intensive online experience combining online sensors, behavioral support and programs improving clinical outcome and reducing healthcare costs www.mydario.com
OTCQB: DRIO Personalized Treatment Overall Diabetes Management Decision Support www.mydario.com
OTCQB: DRIO Lancing device Smart Meter plugs into smart mobile devices (one device iOS + Android) 25 Strip Cartridge – GOD technology Compact Tiny blood sample Highly accurate iOS/Android Inexpensive Highly usable - No battery CE Mark granted in September 2013 Potential 2015 FDA approval www.mydario.com
OTCQB: DRIO Patient Supporters • Easier monitoring • Remote followup & support • Auto alerts Payers • Online patient monitoring • Improve compliance • Reduce healthcare costs www.mydario.com
OTCQB: DRIO Basic Feature BGM for All-in one Smartphone BGM Insulin Cellular (Roche Connected (Freestyle, Users connectivity Company Accu- (iBGStar, Verio, (Aviva (Liveongo, Chek iHealth Contour, Expert, Telcare) Mobile) Align, 2in1) Aviva etc.) Insulinx) All-in-one Kit Device Pocket sized Powerless / iOS/Android Information sharing with doctors and relatives Disease Management / / Actionable insights Insulin recommendation Estimated HBA1C Community platform / Mentor platform / Clinical Programs Dario Pricing is competitive comparing to mobile meters Pricing www.mydario.com
OTCQB: DRIO Smartphone Compatible iOS/android compatibility limitations Hardware Dedicated Device Logger Software Disease management Dario Combines Disease Management and Native Mobile Multi Platform for Real Time Monitoring www.mydario.com
OTCQB: DRIO • 85% reimbursement & out of pocket • Disposable strips (recurring revenue model) • Service fees clinical programs • Tele-Care Providers • Meta analysis for Payers and HMO’s • Insurers online monitoring • Clinical studies platform www.mydario.com
OTCQB: DRIO Prescription / Reimbursement B2B B2C Labstyle Innovations - Distributors sales force to Direct online marketing, drive sales through email, App, Facebook, SEO healthcare professionals (GP’s) www.mydario.com
OTCQB: DRIO www.mydario.com
OTCQB: DRIO www.mydario.com
OTCQB: DRIO May 10 th *As of May 25, 2015 www.mydario.com
OTCQB: DRIO www.mydario.com
OTCQB: DRIO Name Experience Headquarters • 20 years of experience in building product organizations – from Design to Erez Raphael commercialization. Israel Chairman and CEO • Formerly with Amdocs (NYSE: DOX) and Nokia-Siemens. • 25 years of experience with public and private medical device companies Zvi Ben-David • CFO of Given Imaging Ltd. (formerly Nasdaq: GIVN), and UltraShape Medical Israel CFO Ltd. • David Edelman Entrepreneur and patient advocate who has dedicated his career to using technology to improve health and happiness. Director Product U.S. • President of Diabetes Daily, a leading online community and educational Strategy platform. • 16 years of executive leadership in the Medical Device Industry. Eran Kurma n • Israel Extensive experience in global strategic marketing, business development, VP, Global Strategy and clinical development knowledge. Dror Bacher • 15 years of software business experience Israel • Managing product development at mobile and semi-conductor companies. VP R&D www.mydario.com
OTCQB: DRIO Name Experience • Head of Diabetes Unit and Research Center, Hadassah Medical Center Prof Itamar Raz, MD • Israel National Council of Diabetes of the Israel Ministry of Health Head of SAB • President, Israel Diabetes Research Group. • Type 1 diabetes since 1985 acknowledged as the 2014 Diabetes Educator of the Year by the American Association of Diabetes Educators. Gary Scheiner, CDE MS • Known for his globally-available coaching services at IntegratedDiabetes.com. • An internationally recognized expert in the behavioral aspects of diabetes management. Dr. William Polonsky, PhD • Co-founded the Behavioral Diabetes Institute Author of numerous books on Diabetes. • Dietitian and diabetes educator for nearly thirty-five years. Hope Warshaw, MMSc • Owner of consulting practice, for corporate consulting to consumer and professional writing and RD CDE BC-ADM individual diabetes and weight management counseling. • Former Senior Medical Advisor at Eli Lilly, held teaching positions at Ohio University and Dr. Paul Rosman Northeastern Ohio Universities College of Medicine • Former President or Chair of American Diabetes Association, American Association of Clinical DO FACP FACE FACOI Endocrinologists, and the Ohio Diabetes Prevention and Control Program • Professor of Endocrinology and Metabolic Diseases, • Head of Department at the University Campus Bio-Medico in Rome, Italy Dr. Paolo Pozzilli, MD • Professor of Diabetes Research at St. Bartholomew’s and the London School of Medicine. • Professor of Medicine, Endocrinologist and Angiologist at the Munich Diabetes Research Group in Dr. Eberhard Standl,MD Germany. Has developed his career in both Munich, and at the Joslin Diabetes Center in Boston. www.mydario.com
OTCQB: DRIO www.mydario.com
Recommend
More recommend
